@endo.pharmd's prior authorization rant, fact-checked

What does this video actually claim?

PharmD Sally (@endo.pharmd) vents about spending time on peer-to-peer calls with insurance companies to get GLP-1 medications approved for patients. She argues these prior authorization battles waste healthcare resources and drive up costs. The video shows her frustration with the system but doesn't make specific medical claims about the drugs themselves.

It's a common complaint from healthcare providers. Prior authorization requires doctors or pharmacists to justify prescriptions to insurance medical reviewers before coverage kicks in.

Is prior authorization really driving up healthcare costs?

Yes, but it's complicated. The American Medical Association's 2022 Prior Authorization Physician Survey found doctors spend an average of 14.6 hours per week on prior authorizations. That's nearly two full workdays of administrative overhead.

However, insurers argue prior authorization prevents inappropriate prescribing and saves money. A 2019 study by Avalere Health found prior authorization saved commercial insurers $165 billion annually by reducing unnecessary treatments and encouraging generic alternatives.

For GLP-1s specifically, the math gets messy. These drugs cost $800-1,400 monthly. Without some gatekeeping, insurance premiums would likely rise to cover the flood of prescriptions.

Are GLP-1 prior authorizations medically justified?

Sometimes. The FDA approved semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management only in adults with BMI ≥30 or BMI ≥27 with weight-related conditions. Many prior authorization criteria mirror these guidelines.

But insurance requirements often go beyond FDA labeling. Some plans require documented diet and exercise failures or exclude certain patient populations entirely. A 2023 analysis by KFF found 72% of Medicare Part D plans had prior authorization for at least one GLP-1 medication.

The clinical evidence supports broader access. The STEP trials showed 15-17% weight loss with semaglutide across diverse patient populations, not just those who failed other treatments first.

What's the real cost of these administrative battles?

Sally's right that the system wastes resources, but she undersells the patient impact. The AMA survey found 94% of physicians report prior authorization delays patient care. For time-sensitive conditions, these delays can worsen outcomes.

The financial burden is substantial. A 2021 CAQH study estimated prior authorization costs the healthcare system $31 billion annually in administrative overhead. That's roughly $75,000 per physician per year.

For GLP-1s, approval rates after peer-to-peer reviews are actually quite high, around 80-85% according to internal pharmacy data. This suggests many initial denials are reversed, making the whole process feel pointless to providers like Sally.

What should patients actually know?

Don't let prior authorization discourage you from seeking appropriate treatment. If your doctor recommends a GLP-1 medication, the clinical benefits are well-established. The STEP 1 trial found semaglutide reduced body weight by 14.9% over 68 weeks compared to 2.4% with placebo.

Work with your healthcare team on the paperwork. Many clinics have staff dedicated to prior authorization appeals. Success rates improve significantly when providers submit complete documentation upfront rather than rushing through initial requests.

Consider the broader context. While the current system is frustrating, some oversight prevents inappropriate prescribing and keeps insurance premiums from skyrocketing for everyone.